scholarly journals Optimal timing for blastomere biopsy of 8-cell embryos for preimplantation genetic diagnosis

2017 ◽  
Vol 33 (1) ◽  
pp. 32-38 ◽  
Author(s):  
Y Kalma ◽  
L Bar-El ◽  
S Asaf-Tisser ◽  
M Malcov ◽  
A Reches ◽  
...  
Keyword(s):  
Preimplantation Genetic Diagnosis ◽  
Genetic Diagnosis ◽  
Optimal Timing ◽  
Blastomere Biopsy

Does blastomere biopsy in preimplantation genetic diagnosis (PGD) affect early serum hCG level?

2007 ◽  
Vol 88 ◽  
pp. S64-S65
Author(s):  
Y.J. Cho ◽  
J.H. Jun ◽  
J.Y. Kim ◽  
I.O. Song ◽  
M.K. Koong ◽  
...  
Keyword(s):  
Preimplantation Genetic Diagnosis ◽  
Genetic Diagnosis ◽  
Blastomere Biopsy

scholarly journals Embryo biopsy and development: the known and the unknown

Reproduction ◽  
2017 ◽  
Vol 154 (5) ◽  
pp. R143-R148 ◽  
Author(s):  
Federica Zacchini ◽  
Roberta Arena ◽  
Adam Abramik ◽  
Grazyna E Ptak
Keyword(s):  
Clinical Practice ◽  
Preimplantation Genetic Diagnosis ◽  
Current Knowledge ◽  
Genetic Diagnosis ◽  
In Utero ◽  
Human Reproduction ◽  
Embryo Biopsy ◽  
Postnatal Life ◽  
Long Term Effects ◽  
Blastomere Biopsy

Preimplantation genetic diagnosis (PGD) has been introduced in clinical practice as a tool for selecting ‘healthy’ embryos before their transfer in utero. PGD protocols include biopsy of cleaving embryos (blastomere biopsy (BB)) or blastocysts (trophectoderm biopsy (TB)), followed by genetic analysis to select ‘healthy’ embryos for transfer in utero. Currently, TB is replacing the use of BB in the clinical practice. However, based on the European Society of Human Reproduction and Embryology Preimplantation Genetic Diagnosis Consortium reports, BB has been used in >87% of PGD cycles for more than 10 years. An exhaustive evaluation of embryo biopsy (both BB and TB) risks and safety is still missing. The few epidemiological studies available are quite controversial and/or are limited to normalcy at birth or early childhood. On the other hand, studies on animals have shown that BB can be a risk factor for impaired development, during both pre- and postnatal life, while little is known on TB. Thus, there is an urgent need of focused researches on BB, as it has contributed to give birth to children for more than 10 years, and on TB, as its application is significantly growing in clinical practice. In this context, the aim of this review is to provide a complete overview of the current knowledge on the short-, medium- and long-term effects of embryo biopsy in the mouse model.

The Outcomes of Preimplantation Genetic Diagnosis Therapy in Treatment of β Thalassemia - a Retrospective Analysis.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3783-3783
Author(s):  
Naveen Qureshi ◽  
Drucilla Foote ◽  
Rebecca Madore ◽  
Mark C. Walters ◽  
Sylvia Titi Singer ◽  
...  
Keyword(s):  
Preimplantation Genetic Diagnosis ◽  
Therapeutic Option ◽  
Single Gene ◽  
Genetic Diagnosis ◽  
Human Leukocyte ◽  
Hematopoietic Stem ◽  
Vitro Fertilization ◽  
Blastomere Biopsy ◽  
Sibling Donor

Abstract BACKGROUND: β thalassemia is one of the most common single gene disorders. Hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-identical sibling donor is a curative option that minimizes the risk of graft-versus-host disease, compared to alternative donor HCT. In families that have an affected child, preimplantation genetic diagnosis (PGD) can be utilized to select an unaffected embryo that is HLA-identical. Briefly, this procedure requires in vitro fertilization, oocyte retrieval, fertilization and blastomere biopsy for preimplantation analysis and identification of unaffected HLA-identical embryos. After delivery, umbilical cord blood from the sibling donor is collected for HCT. In our institution, PGD has been pursued as a therapeutic option by families with thalassemia. The estimated cost of this uninsured procedure is $20,000 per cycle. METHODS: Families affected with β thalassemia who attempted PGD were identified and reviewed for indication, attempted cycles, successful pregnancy and transplantation outcome. RESULTS: Eight identified families affected by thalassemia underwent PGD. The diagnosis of their affected children included: 6 cases of β thalassemia major and 2 cases of transfusion dependent E β thalassemia patients. A total of 14 cycles of PGD were attempted, ranging from 1–4 attempts per family. Following successful identification of HLA-identical cells, 2 pregnancies occurred (1 early miscarriage, 1 successful delivery). This pregnancy resulted in the engraftment of a β thalassemia child. CONCLUSION: PGD including selection of HLA-identical sibling embryos is a novel, therapeutic approach for patients with β thalassemia. While this offers the possibility of recruiting a suitable donor for HCT, it is limited by significant financial and emotional burdens that it places on families affected with β thalassemia. Improvements in its efficiency and cost will make this a more viable option for affected families.

Different embryonic development after blastomere biopsy for preimplantation genetic diagnosis, observed by time-lapse imaging

2009 ◽  
Vol 92 (4) ◽  
pp. 1470-1471 ◽  
Author(s):  
Yukihiro Terada ◽  
Tomohisa Ugajin ◽  
Hisataka Hasegawa ◽  
Hiroshi Nabeshima ◽  
Nobuo Yaegashi
Keyword(s):  
Embryonic Development ◽  
Preimplantation Genetic Diagnosis ◽  
Genetic Diagnosis ◽  
Time Lapse ◽  
Blastomere Biopsy ◽  
Time Lapse Imaging
Sign in / Sign up

Export Citation Format

Share Document